^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    18h
    A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy (clinicaltrials.gov)
    P2, N=180, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab)
    22h
    SWOG S2302: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study (clinicaltrials.gov)
    P3, N=700, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Mar 2025 --> Jan 2027
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • HER-2 mutation • MET mutation
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    22h
    DIAL: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (clinicaltrials.gov)
    P2/3, N=1360, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Trial primary completion date: Jan 2025 --> May 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed
    22h
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial primary completion date: Aug 2027 --> Jan 2027
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    22h
    Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Stanford University | Trial primary completion date: Dec 2024 --> Oct 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • magrolimab (ONO-7913)
    1d
    Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2025 --> Oct 2025
    Trial completion date
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    1d
    COMET: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (clinicaltrials.gov)
    P3, N=133, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • paclitaxel • docetaxel • pemetrexed • vinorelbine tartrate • Tepmetko (tepotinib)
    1d
    Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (clinicaltrials.gov)
    P2/3, N=700, Recruiting, Vasgene Therapeutics, Inc | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    EPHB4 (EPH receptor B4)
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv) • sEphB4-HSA
    1d
    PENELOPE: First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer (clinicaltrials.gov)
    P2, N=92, Recruiting, Yonsei University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • nesuparib (JPI-547)
    1d
    Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report. (PubMed, Case Rep Oncol)
    The initial treatment regimen included carboplatin, etoposide, and durvalumab. After four courses of cisplatin and irinotecan therapy, pembrolizumab was introduced, and a complete response (CR) was maintained for 18 months. We report a rare case of a long-term response to pembrolizumab in ED-SCLC with TMB-high, highlighting the potential for targeted immunotherapy in such cases.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    FoundationOne® CDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV • irinotecan
    2d
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin
    2d
    A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
    2d
    CORINTH: Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus (clinicaltrials.gov)
    P1, N=50, Recruiting, Cardiff University | Phase classification: P1b --> P1 | Trial completion date: Nov 2022 --> Nov 2026 | Trial primary completion date: Nov 2022 --> Nov 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • capecitabine • mitomycin
    2d
    Efficacy and safety of Peg-IFNα2b combined with pembrolizumab and GP in the treatment of intrahepatic cholangiocarcinoma (ChiCTR2500099858)
    P=N/A, N=19, Not yet recruiting, Zhongshan Hospital Fudan University Xiamen Branch; Zhongshan Hospital Fudan University Xiamen Branch
    New trial
    |
    Keytruda (pembrolizumab)
    2d
    A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02 (ChiCTR2500099840)
    P3, N=700, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)
    3d
    International Multicentric Study ARON-1 (clinicaltrials.gov)
    P=N/A, N=1220, Recruiting, Hospital of Macerata | Trial completion date: Dec 2024 --> Sep 2027
    Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib)
    3d
    Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor (clinicaltrials.gov)
    P2, N=14, Terminated, Yonsei University | N=30 --> 14 | Trial completion date: Dec 2025 --> Mar 2025 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Mar 2025; According to the protocol criteria, during the Phase 1 analysis, the registered participants' imaging evaluation responses did not meet the criteria, leading to an early termination
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • vactosertib (TEW-7197)
    3d
    PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report. (PubMed, JTO Clin Res Rep)
    Most patients received pembrolizumab (93%) and were treated with stereotactic radiation (81%)...Although high PD-L1 levels are associated with longer survival and improved intracranial control, radiation necrosis occurs more frequently in patients with high PD-L1 expression. Clinicians should be aware of long-term treatment-related toxicities in this population.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab)
    3d
    PlugIN: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Grupo Español Multidisciplinar de Melanoma
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    3d
    A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=109, Completed, Takeda | Active, not recruiting --> Completed | N=49 --> 109 | Trial completion date: Nov 2025 --> Oct 2024 | Trial primary completion date: Nov 2025 --> Oct 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement • ALK fusion
    |
    Keytruda (pembrolizumab) • subasumstat (TAK-981)
    3d
    Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Andrew Hendifar, MD | Trial completion date: Feb 2025 --> Feb 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)
    3d
    A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Homozygous MTAP-Deletion Advanced Thoracic Tumors (Master Protocol) (ChiCTR2500095932)
    P=N/A, N=312, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New trial
    |
    PD-L1 (Programmed death ligand 1) • MTAP (Methylthioadenosine Phosphorylase)
    |
    PD-L1 expression • MTAP deletion
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • AMG 193
    3d
    Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, The University of Texas Health Science Center at San Antonio | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • defactinib (VS-6063)
    3d
    STRIKE: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (clinicaltrials.gov)
    P3, N=1040, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    Keytruda (pembrolizumab) • Fotivda (tivozanib)
    3d
    Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. (PubMed, Nat Med)
    Based on the high levels of programmed cell death protein 1 in the infused TILs, pembrolizumab was added to the regimen (SEL-TIL + P), and eight objective responses were seen in 34 patients (23.5% (95% CI: 12.4-40.0))...These results could potentially provide a cell-based treatment in a population not traditionally expected to respond to immunotherapy. ClinicalTrials.gov identifier: NCT01174121 .
    P2 data • Journal • Tumor-infiltrating lymphocyte
    |
    PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab)
    3d
    TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. (PubMed, Cell Rep Med)
    Collectively, these data support a role for MTL-CEBPA in reducing immunosuppression in the TME. This study was registered at ClinicalTrials.gov (NCT04105335).
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    Keytruda (pembrolizumab) • MTL-CEBPA
    3d
    Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-targeted therapy in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC) and Thymic Epithelial Tumors (TET). (PubMed, Oncol Res Treat)
    Deescalation of therapy was the aim of low-dose versus standard-dose Pembrolizumab in advanced NSCLC. Preliminary data in thymic epithelial tumors (TET) and immune-checkpoint-inhibitor (ICI) therapy in combination with Lenvatinib were presented in the PECATI trial.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    4d
    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy (clinicaltrials.gov)
    P2, N=80, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    4d
    Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    4d
    Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    4d
    Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC) (clinicaltrials.gov)
    P=N/A, N=242, Completed, Hospital Universitario Araba | Recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Bavencio (avelumab)
    4d
    Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Emory University | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    4d
    Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma (clinicaltrials.gov)
    P3, N=186, Not yet recruiting, University of Sao Paulo General Hospital | Trial completion date: Jan 2027 --> Jan 2029 | Initiation date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    4d
    Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Recruiting, Ruijin Hospital | N=60 --> 34 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation
    |
    Keytruda (pembrolizumab)
    4d
    KEYNOTE-F91: Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) (clinicaltrials.gov)
    P3, N=756, Recruiting, Immutep S.A.S. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • ImmuFact (eftilagimod alpha)
    4d
    IMPROVE: Probiotics in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=222, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Aidixi (disitamab vedotin) • Padcev (enfortumab vedotin-ejfv)
    4d
    Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment? (PubMed, Pathol Oncol Res)
    Patients with COPD were at increased risk of developing autoimmune thyroiditis compared to non-COPD patients (OR 3.9 95% CI 1.135-13.260, p = 0.0227). Our study showed that patients dealing with COPD have a 3.9 times greater risk of developing autoimmune thyroiditis as an adverse event during Pembrolizumab treatment compared with patients without COPD.
    Observational data • Retrospective data • Journal • Adverse events • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab)
    4d
    Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab. (PubMed, Gynecol Oncol Rep)
    After cytoreductive surgery, carboplatin and paclitaxel chemotherapy, and radiation therapy, the patient experienced progression with widespread metastases. Although toxicities can require treatment adjustments, they can often be effectively managed, allowing for prolonged therapy. Further research is needed to determine the optimal treatment duration and strategies to mitigate long-term side effects.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-L
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lenvima (lenvatinib)
    4d
    A case of triple-negative breast cancer with thalassemia manifested by anemia progression during neoadjuvant chemotherapy. (PubMed, Int Cancer Conf J)
    Pembrolizumab, paclitaxel, and carboplatin were administered every 3 weeks, during which the hemoglobin (Hb) level gradually decreased...This included 4 cycles of pembrolizumab, doxorubicin, and cyclophosphamide. Subsequently, a partial mastectomy plus sentinel lymph node biopsy was performed, and the patient achieved a pathological complete response. This case demonstrates that neoadjuvant chemotherapy for breast cancer can be successfully completed with appropriate blood transfusion support in patients with thalassemia-induced anemia.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    4d
    Immune checkpoint inhibitor restores daily function in patient with microsatellite instability (MSI)-high advanced endometrial cancer and poor performance status. (PubMed, Int Cancer Conf J)
    Pembrolizumab was initiated and continued for 19 courses, after which lesions had disappeared or calcified, leading to drug discontinuation...In such cases, ICI can rapidly improve overall condition, a phenomenon known as a Lazarus-type response, as seen in other cancers such as non-small cell lung cancer. The online version contains supplementary material available at 10.1007/s13691-025-00752-3.
    Journal • Checkpoint inhibition • Microsatellite instability
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    4d
    Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer. (PubMed, Int Cancer Conf J)
    The use of an immune checkpoint inhibitor pembrolizumab resulted in durable partial response of metastatic lung tumors. This case reminds clinicians of the rare possibility of multiple germline variants in MMR genes in individuals with Lynch syndrome.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    Keytruda (pembrolizumab)
    4d
    Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors. (PubMed, Int Cancer Conf J)
    Following surgery, she demonstrated a partial response to six cycles of conventional paclitaxel and carboplatin. She then received maintenance treatment with niraparib; however, disease progression subsequently occurred. The patient was treated with pembrolizumab and is currently receiving treatment with a partial response. Previous reports have demonstrated the efficacy of immune checkpoint inhibitors in 5 out of 6 cases of malignant transformation of mature teratomas, and this treatment appears to be a promising strategy. The online version contains supplementary material available at 10.1007/s13691-024-00740-z.
    Journal • Checkpoint inhibition • Tumor mutational burden • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • HRD • PTEN mutation
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Zejula (niraparib)